A recent Phase III clinical trial, TRIUMPH-2, evaluated the efficacy and safety of retatrutide, a triple receptor agonist and experimental once-weekly injection being developed to treat obesity and type 2 diabetes. What sets it apart from drugs such as semaglutide (Wegovy), which targets one hormone, and tirzepatide (Zepbound), which targets two, is its ability to activate three hormone receptors at once.